BRIEF published on 12/11/2025 at 23:05, 2 months 8 days ago Xenetic Biosciences ajourne son assemblée générale annuelle des actionnaires de 2025. Instructions De Vote Quorum Biosciences Xénétiques Assemblée Générale Des Actionnaires Ajournement De 2025
BRIEF published on 12/11/2025 at 23:05, 2 months 8 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 2 months 8 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 3 months 1 day ago Xenetic Biosciences étend sa collaboration avec Scripps Research Biopharmaceutique Traitement Du Cancer DNase I Thérapie CAR-T Recherche Scripps
BRIEF published on 11/19/2025 at 14:50, 3 months 1 day ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 3 months 1 day ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 3 months 7 days ago Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
BRIEF published on 11/13/2025 at 14:50, 3 months 7 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 3 months 7 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 4 months 10 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
Published on 02/20/2026 at 15:45, 1 hour 28 minutes ago Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 2 hours 43 minutes ago Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 14:08, 3 hours 5 minutes ago Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange
Published on 02/20/2026 at 14:00, 3 hours 13 minutes ago Nextech3D.ai's Eventdex Platform Powers AI Matchmaking for the SBA's CT Business Matchmaker Event Featuring Government Agencies and Major Prime Contractors
Published on 02/20/2026 at 13:30, 3 hours 43 minutes ago ESGold Launches 70 km2 District-Scale ANT Survey at Montauban Following 3D Model Identifying Deep, Expanding 2 km Mineralized Corridor
Published on 02/20/2026 at 17:05, 8 minutes ago Eurobattery Minerals publishes its year-end report for 2025 while working on design & construction of the tungsten processing plant at San Juan
Published on 02/20/2026 at 15:24, 1 hour 48 minutes ago Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 02/20/2026 at 15:23, 1 hour 49 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 02/20/2026 at 09:28, 7 hours 45 minutes ago Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 31 janvier 2026
Published on 02/20/2026 at 09:28, 7 hours 45 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of January 31, 2026
Published on 02/20/2026 at 07:30, 9 hours 43 minutes ago Aankondiging inkoop eigen aandelen in het kader van een aandelenaankoopplan
Published on 02/20/2026 at 07:30, 9 hours 43 minutes ago Announcement of share buyback in the context of a share purchase plan
Published on 02/20/2026 at 07:30, 9 hours 43 minutes ago Announcement of share buyback in the context of a share purchase plan
